Transitional Probability-Based Model for HPV Clearance in HIV-1-Positive Adolescent Females

Julia Kravchenko1*, Igor Akushevich2, Staci L. Sudenga3, Craig M. Wilson3, Emily B. Levitan3, Sadeep Shrestha3*

1 Duke Cancer Institute, Duke University Medical Center, Duke University, Durham, North Carolina, United States of America, 2 Center for Population Health and Aging, Duke University, Durham, North Carolina, United States of America, 3 Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America

Abstract

Background: HIV-1-positive patients clear the human papillomavirus (HPV) infection less frequently than HIV-1-negative. Datasets for estimating HPV clearance probability often have irregular measurements of HPV status and risk factors. A new transitional probability-based model for estimation of probability of HPV clearance was developed to fully incorporate information on HIV-1-related clinical data, such as CD4 counts, HIV-1 viral load (VL), highly active antiretroviral therapy (HAART), and risk factors (measured quarterly), and HPV infection status (measured at 6-month intervals).

Methodology and Findings: Data from 266 HIV-1-positive and 134 at-risk HIV-1-negative adolescent females from the Reaching for Excellence in Adolescent Care and Health (REACH) cohort were used in this study. First, the associations were evaluated using the Cox proportional hazard model, and the variables that demonstrated significant effects on HPV clearance were included in transitional probability models. The new model established the efficacy of CD4 cell counts as a main clearance predictor for all type-specific HPV phylogenetic groups. The 3-month probability of HPV clearance in HIV-1-infected patients significantly increased with increasing CD4 counts for HPV16/16-like (p<0.001), HPV18/18-like (p<0.001), HPV56/56-like (p=0.05), and low-risk HPV (p<0.001) phylogenetic groups, with the lowest probability found for HPV16/16-like infections (21.60±1.81% at CD4 level 200 cells/mm³, p<0.05; and 28.03±1.47% at CD4 level 500 cells/mm³). HIV-1 VL was a significant predictor for clearance of low-risk HPV infections (p<0.05). HAART (with protease inhibitor) was significant predictor of probability of HPV16 clearance (p<0.05). HPV16/16-like and HPV18/18-like groups showed heterogeneity (p<0.05) in terms of how CD4 counts, HIV VL, and HAART affected probability of clearance of each HPV infection.

Conclusions: This new model predicts the 3-month probability of HPV infection clearance based on CD4 cell counts and other HIV-1-related clinical measurements.

Introduction

HIV-1-positive women clear HPV infections 4–10 times more slowly than HIV-1-negative, and HIV-1-infected patients with CD4+ T-lymphocytes cell count (CD4) <200 cells/mm³ show the slowest clearance [1,2]. Understanding the role of immunosuppression in risk of persistence of sexually transmitted human papillomavirus (HPV) infection, a main risk factor for cervical intraepithelial neoplasia and a central etiologic agent of cervical cancer, and clarifying how this risk is modified by other factors (such as co-infections, antiretroviral therapy, and behavioral factors) is important for optimization of follow-up strategy [3]. Information from longitudinal studies about factors that affect the probability of type-specific HPV clearance can be used to estimate the impact of cervical cancer interventions. However, this is often problematic because HPV persistence is loosely defined as detection of the same HPV type at two or more subsequent visits, ranging from 2 months to 7 years [4,5,6,7,8,9], and its probability depends on intervals between the tests. Further, the analysis is complicated by the possibility of co-infections with multiple HPV types as well as by varying length of intervals between missing measurements of HPV status. Analytical methods that can fully utilize real-life heterogeneous data, specifically, clinical data that are unevenly scheduled (for example, at 6 months for HPV and at 3-month intervals for HIV clinical data) could be useful in studies of the factors having an impact on probability of clearance of HPV infection.

Here, we describe a transition probability model for studying the relationship between immune status (based on CD4 cell count) and probability of HPV clearance in HIV-infected patients. The Reaching for Excellence in Adolescent Care and Health (REACH) dataset used in this study planned for measurement of HIV-1
status every 3 months and HPV status every 6 months. As in other cohorts, this study had missing and irregular visit measurements: only 82% of time intervals between measurements of HPV statuses were performed as scheduled (i.e., every 6 months), while other HPV tests were done at 3-, 9-, 12-, or other-month intervals. Analyzing these data with standard techniques would require multiple assumptions about the definition of HPV clearance and censoring time for each individual for time-dependent predictors; as a result, part of the dataset would not be utilized. We have developed transition probability-based models and applied an HPV/HIV co-infected cohort to estimate 3-month HPV clearance probabilities while maximizing all available data for both HIV and HPV in the estimations.

Materials and Methods

Data on 266 HIV-1-positive and 134 high-risk HIV-1-negative adolescent females from the REACH cohort were analyzed. The REACH study design and methods of quarterly follow up with HIV-1 testing, immunophenotyping, HIV-1 RNA viral load (VL) and collection of biological specimens, demographic and behavioral factors, and other clinical data, along with incidence and prevalence of HPV infections, have been previously described [2,10,11]. Briefly, between 1996 and 2000, adolescents aged 12–19 years who were HIV-1-positive and comparable at-risk HIV-1-negative persons were recruited into a longitudinal study at 15 clinical sites in the United States. HIV-1-related clinical data and risk factors were measured every 3 months. At enrollment and every 6 months thereafter, cervical lavage samples were tested for HPV infection by MY09/MY11/HMB01-based PCR and for 30 HPV type-specific probes with a chemiluminescent dot blot procedure [12]. PCR-based HPV data were classified as follows: positive; specific for a given HPV type; or “positive, type unknown” (when the sample was positive for the generic probe but not specific HPV type). PCR amplification of a human β-globin gene segment was used for internal DNA quality control, and samples negative for this assay were excluded from the analysis. For certain types of analyses, HPV types were categorized according to phylogenetic patterns [2,13] into: 1) 16/16-like (16, 31, 52, 38, 67); 2) 18/18-like (18, 39, 43, 59, 26, 51); 3) 56/56-like (56, 33, 66); and 4) low-risk (6, 11, 42, 44, 54, 40, 13, 32, 62, 72, 2, 57, 55). The highly active antiretroviral therapy (HAART) was defined as a combination of two nucleoside reverse transcriptase inhibitors and either a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor, or a zidovudine/lamivudine combination regimen plus another antiretroviral drug. Data on antiretroviral therapy were obtained through interviews and chart reviews for current prescriptions, and adherence data were obtained through interviews as previously described [14].

Ethics Statement

All the participants of the study provided written informed consent in the parent study at the Adolescent Medicine HIV/AIDS Research Network for the REACH project, and the UAB Institutional Review Board approved this sub-study. The parent study and this sub-study conformed to the procedures for informed consent (parental permission was obtained wherever required) approved by institutional review boards at all sponsoring organizations and to human-experimentation guidelines set forth by the United States Department of Health and Human Services. Cox proportional hazard regression was used to test which covariates have significant effects on probability of HPV clearance for each of four phylogenetic HPV types. First, an univariable regression analysis was used for a wide spectrum of variables including demographic characteristics, clinical exams, antiretroviral therapy, behavioral factors, and coinfections (as listed in Table 1). From this, a subset of predictors with significant effects was selected and considered in multivariable analysis. For this analysis, SAS PROC PHREG (Cary, NC) was used.

The model developed in the present paper falls under the general category of transitional Markov models and is referred to as a transitional probability-based model. These kinds of approaches, also known as regressive or conditional models, are used in epidemiology for analyses of dependent binary observations [15,16,17]. The model allows for estimating the probability of changing HPV status in patients with specific HPV type, i.e., a chance to clear HPV infection during the follow-up period. To account for HIV-1-related clinical data such as CD4 count, HIV-1 VL, and other HIV-1-related factors, which were measured every 3 months, HPV infection status was reconstructed for the same time interval considering transition probabilities. The transition probabilities were referred to as \( P_{ij}(x) \), where \( i \) was initial state of type-specific HPV infection \( (i = 0 \) corresponded to absence, and \( i = 1 \) to presence of type-specific HPV infection), and \( j = 0 \) and \( j = 1 \) corresponded to the status of type-specific HPV infection at the end of a 3-month period. Vector \( x \) denoted the set of most influential predictors of HPV clearance probability, such as CD4 count, HIV-1 VL, HAART, and HPV type [2,18]. For example, the probability \( P_{00}(x) \) corresponded to the situations where HPV infection observed at a recent visit was cleared in 3 months.

With this model, the information about missed measurements at odd visits can be reconstructed using the previous and forthcoming measurements (see Figure 1A). The transition probability between two subsequent visits with measured HPV status could be presented as \( P_{ij}(x_i) = P_{00}(x_i) + P_{01}(x_i)P_{11}(x_i) \), where \( i \) and \( j \) describe the HPV status at the first and third visits, respectively. The status at a second visit is unknown, and, therefore, the sum over two possible intermediate states contributes to the observed transition probability between two subsequent even visits. Parameters \( x_i \) and \( x_h \) in the above formula denote the sets of respective predictors for transitions between first-to-second and second-to-third visits, respectively. The likelihood function is the product over all transfers with known HPV status. If data are taken exactly according to the cohort’s measurement design, the likelihood is

\[
L = \prod_{a} P_{00}(x_a) + P_{01}(x_a)P_{11}(x_a) \]

(1)

Here, \( n \) covers all individuals in the dataset, \( k_a \) —all transitions between states with measured HPV virus status represented by indices \( i \) and \( j \) in individual \( l \) and \( x_{0i} \) and \( x_{1i} \) are the vectors of predictors measured at the beginning of time period of respective transition. The dependence of transition probabilities on predictors are modeled in logistic regression style as:

\[
P_{00}(x) = \frac{1}{1 + \exp(u_0 + \sum_i \beta_{0i}x_{0i})}, \quad P_{01}(x) = 1 - P_{00}(x)
\]

(2)

\[
P_{11}(x) = \frac{1}{1 + \exp(u_1 + \sum_i \beta_{1i}x_{1i})}, \quad P_{10}(x) = 1 - P_{11}(x)
\]

where intercepts \( u_0 \) and \( u_1 \) refer to logarithms of odds of changing the type-specific HPV status for zeroth values of predictors, and parameters \( \beta_{0i} \) and \( \beta_{1i} \) describe the effects of respective predictors [19].

If the number of missed HPV status is 0 (zeroth) or varies from two to five, the likelihood function could be generalized by
summing over all intermediate states. For example, for transitions with three missed HPV statuses (see Figure 1B), the contribution to the likelihood function could be presented as:

$$\sum_{m_1} \sum_{m_2} \sum_{m_3} P_{m_1}(x_{m_1})P_{m_2}(x_{m_1m_2})P_{m_3}(x_{m_1m_2m_3})P_{m_4}(x_{m_1m_2m_3m_4}),$$

where $m_1$, $m_2$, and $m_3$ are unmeasured (0 or 1) HPV status in three intermediate states. The set of observed transfers with measured HPV statuses for a specific type of HPV virus or for HPV group is the input dataset for likelihood maximization. Note that CD4 count and HIV-1 VL also could have missing measurements; however, the appearance of these missing variables is not related to the study design, so we assume that they are missing at random, and any standard approach for filling missing data at random can be applied (e.g., imputation with the mean conditional on observed values of other variables or simply linear interpolation). Because in the REACH cohort, the fractions of missing values of predictors of HPV clearance were relatively small (about 2% for CD4 count in HIV-1-positive patients, about 5% for HIV-1 VL, and about 1% for HAART), no notable impact of specific scheme of their filling was expected. The reported results were obtained using a linear interpolation to fill missing values in the predictors (but not HPV) status.

To test the different hypotheses regarding the possible effects of different potential predictors on probability of HPV clearance, a two-stage approach was designed. The two-stage approach complemented the advantages of methods used at each stage such as nonparametric estimates of hazard ratios in the Cox model and opportunities for evaluating 3-month probabilities for models (1) – (3). The comparison of the results obtained from both approaches allows for validating the properties of the new method. At the first stage, the effects were evaluated using the Cox proportional hazard model, and then the variables that demonstrated significant effects in this model were obtained using a linear interpolation to fill missing values in (3).

Table 1. Demographic, behavioral, and clinical characteristics of adolescent female study participants from the REACH cohort.

| Variable                                      | HIV-1-positive | HIV-1-negative | OR (95% CI) |
|-----------------------------------------------|----------------|----------------|-------------|
| Number of patients                            | N = 262        | N = 134        | -           |
| Age, years$^1$                                | 16.8 (1.1)     | 16.6 (1.2)     | -           |
| Number of visits per patient$^1$              | 11.0 (4.88)    | 8.7 (4.36)$^2$ | -           |
| Number of visits per patient with measured HPV status$^1$ | 5.6 (2.5)      | 4.7 (2.6)$^1$ | -           |
| Race$^2$                                      |                |                |             |
| African Americans                             | 206 (78.6%)    | 92 (68.7%)     | 1.79 (0.81–3.98)$^1$ |
| Caucasians                                    | 15 (5.7%)      | 12 (9.0%)      | Referent    |
| Others                                        | 41 (15.6%)     | 30 (22.4%)     | 1.09 (0.45–2.67) |
| Baseline CD4+ T cell count, cells/mm$^3$      | 535.2 (263.6)  | 896.5 (258.9)$^1$ | -  |
| Number of lifetime sexual partners$^2$        |                |                |             |
| <6                                            | 81 (30.9%)     | 54 (40.3%)     | Referent    |
| 6–15                                          | 104 (39.7%)    | 43 (32.1%)     | 1.61 (0.98–2.85) |
| >15                                           | 77 (29.4%)     | 37 (27.6%)     | 1.39 (0.82–2.34) |
| Ever smoked cigarettes$^2$                    |                |                |             |
| Never smoked                                  | 33 (12.6%)     | 20 (14.9%)     | 0.81 (0.44–1.49) |
| Smoked ($\geq$100 cigarettes)                 | 205 (78.2%)    | 101 (75.4%)    | Referent    |
| Trichomonas infection$^3$                     |                |                |             |
| Negative                                      | 219 (83.6%)    | 128 (95.5%)$^3$| Referent    |
| Positive                                      | 34 (13.0%)     | 2 (1.5%)       | 9.93 (2.35–42.03)$^2$ |
| Gonorrhea infection$^2$                       |                |                |             |
| Negative                                      | 208 (79.4%)    | 104 (77.6%)    | Referent    |
| Positive                                      | 22 (8.4%)      | 9 (6.7%)       | 1.22 (0.54–2.75) |
| Chlamydia infection$^2$                       |                |                |             |
| Negative                                      | 182 (69.5%)    | 90 (67.2%)     | Referent    |
| Positive                                      | 50 (19.1%)     | 26 (19.4%)     | 0.95 (0.56–1.62) |
| HIV VL, logarithm$^4$                         | 3.44 (1.01)    | -              | -           |
| Currently taking ART medications$^2$          |                |                |             |
| Not on ART drugs                              | 125 (47.7%)    | -              | -           |
| Mono or combination therapy without PI        | 101 (38.5%)    | -              | -           |
| Combo therapy with PI                         | 35 (13.4%)     | -              | -           |
| ART therapy ever used$^2$                    |                |                |             |
| No ART was used                               | 98 (37.4%)     | -              | -           |
| Mono or combination therapy without PI        | 105 (40.0%)    | -              | -           |
| Combo therapy with PI                         | 57 (21.8%)     | -              | -           |
| ART regimen unknown                           | 2 (0.8%)       | -              | -           |

Notes: $^1$ – results are presented as mean (SD); $^2$ – number of cases (percent); $^3$ – p < 0.05 for the difference between HIV-1-positive and HIV-1-negative: continuous variables were analyzed by general linear model, and categorical were analyzed by chi-square; $^4$ – p < 0.05 for the difference with the referent group; continuous variables were analyzed by general linear model, and categorical were analyzed by PROC LOGISTIC. doi:10.1371/journal.pone.0030736.t001
Moreover, the specific assumptions also are required to decide how to treat missing data on unknown HPV status. There is no consensus in literature about the choice of specific assumptions in these situations. Based on the published studies, our set of assumptions included: 1) time of HPV incidence was 90 days before the first exam with positive HPV status; 2) patient was

**Figure 1. Reconstruction of information about the missed measurements when one HPV status is unknown (Figure 1A) or several (e.g., three) HPV statuses in a raw are missed (Figure 1B).** Here, \( x \) denotes the set of predictors of HPV clearance probability, such as CD4 count, HIV-1 VL, HAART, and HPV type. When one HPV measurement is unknown (Figure 1A), \( i \) and \( j \) describe the HPV status at the first and third visits, respectively, and parameters \( x_a \) and \( x_b \) denote the sets of predictors for transitions between first-to-second and second-to-third visits, respectively. The probability of changing HPV status from the first (i.e., known) state of HPV infection \( i \) to the status of HPV infection at the second visit (i.e., unknown) is \( P_{i0}(x_a) \) when HPV status at the second visit is negative (i.e., “0”) or \( P_{i1}(x_a) \) when it is positive (i.e., “1”). Respectively, at the third visit (with measured/known HPV status) HPV status \( j \) can be defined as \( P_{0j}(x_b) \) when at the second visit it supposed to be HPV-negative, and \( P_{1j}(x_b) \) when at the second visit it supposed to be HPV-positive. The sum over two possible intermediate states contributes to the total transition probability; so, the transition probability between two subsequent visits with measured HPV status could be presented as \( P_{i0}(x_a)P_{0j}(x_b) + P_{i1}(x_a)P_{1j}(x_b) \). When three subsequent HPV status are unknown (Figure 1B), there are eight different combinations of HPV statuses in these states, each denoted by \( m_1 \), \( m_2 \), and \( m_3 \) as unmeasured HPV statuses which can be 0 or 1. Therefore, the transition probability between states with known HPV statuses is calculated as three-fold sum over all combinations of HPV statuses in these three unmeasured states.

Furthermore, the specific assumptions also are required to decide how to treat missing data on unknown HPV status. There is no consensus in literature about the choice of specific assumptions in these situations. Based on the published studies, our set of assumptions included: 1) time of HPV incidence was 90 days before the first exam with positive HPV status; 2) patient was
Probability of HPV Clearance

The main characteristics of studied patients are listed in Table 1. The average age of HIV-1-infected adolescent females were 16.8 (±1.1) years old, and 78.6% of them were African Americans. On average, they had about 11 HIV-1 status-related visits/examinations per patient (quarterly); however, HPV data were collected only biannually, so during half of these visits. Table 2 provides detailed descriptions of incident and prevalent HPV infections: among oncogenic HPVs, HPV16, 31, 32, and 67 (HPV16/16-like group), HPV59 and 26 (HPV18/18-like group), and HPV56 and 53 (HPV56/56-like group) were more often (p<0.05) registered in HIV-1-infected than HIV-1-negative patients.

The results of the Cox proportional hazard analysis for HIV-1-infected adolescent females are shown in Table 3. No significant HRs were obtained for such parameters as having <6 or >15 lifetime sexual partners, ever being a smoker, or being infected with Trichomonas vaginalis or Neisseria gonorrhoea. CD4 count was a consistent predictor for clearance of HPV16/16-like, 18/18-like, and low-risk groups. For these HPV groups, a significantly higher probability of HPV clearance was at CD4 levels higher than 500 cells/mm³ (compared with those at <500 cells/mm³); the difference was especially pronounced for CD4 categorical cutout at 200 cells/mm³. For HIV-1 VL, significant effect on HPV clearance (for all except HPV56/56-like group) was observed only without CD4 count as a second parameter (in the univariable analysis). While being on HAART was a significant predictor of HPV16/16-like clearance only, being on HAART with PI significantly increased probability of clearance of 16/16-like, 18/18-like, and low-risk HPV infection. Also, being infected with Chlamydia trachomatis could be a positive predictor for low-risk HPV clearance.

Sensitivity analysis was performed to check the stability of HRs estimated by the Cox model. In many cases, the HRs essentially shifted when assumptions changed: e.g., the effect of CD4 being >200 cells/mm³ changed for HPV16/16-like infection from 1.68 to 1.86, and from 2.53 to 3.07 (still remaining significant) when 365 days were used in assumptions #2 and #3 instead of 450 days. Another example is the changes of the HAART effect from 1.77 to 2.03 for HPV16/16-like infection, which remained highly significant while using 270 days instead of 450 in these assumptions.

The results obtained from the basic model and from the models describing the effects of HIV-1 VL and HAART (with PIs) are shown in Table 4, and the results obtained from all models [M1–

\[ M2 \] —includes the effect of the presence of HIV-1 infection on intercept of \( u_1 + \beta_1 \cdot CD4 + \beta_2 \cdot \xi_{HIV} \), where \( \xi_{HIV} \) is the binary variable characterizing the HIV-1 seropositivity (\( \xi_{HIV} = 1 \)) or HIV-1 seronegativity (\( \xi_{HIV} = 0 \)). While the base model M1 is applied separately for HIV-1-positive and HIV-1-negative patients, the M2 as well as the M3 models are designed to investigate whether and how specifically the effect of CD4 counts on HPV clearance probability is influenced by the presence of HIV-1 infection, which may have an effect on HPV clearance beyond the CD4 counts effect (e.g., this effect could be further compared with the patients with other immunodeficiencies such as those with organ transplants or inherited immune disorders).

\[ M3 \] —extends the M2 model by including the possible interference of the effects of HIV-1 seropositivity and CD4 count on HPV clearance \( u_1 + \beta_1 \cdot CD4 + \beta_2 \cdot CD4 \cdot \xi_{HIV} \). This model evaluates the modifying effect of CD4 on HPV clearance by the presence of HIV-1-infection.

\[ M4 \] —in HIV-1-infected patients, it introduces CD4 count as a squared parameter in \( P_2(x) \) (the exponent argument is \( u_1 + \beta_1 \cdot CD4 + \beta_2 \cdot CD4^2 \)) to test the assumption about non-linearity (squared CD4) in interrelations between CD4 count and HPV clearance probability in HIV-1-positive patients.

\[ M5 \] —in HIV-1-positive patients, the effect of CD4 count is described as a piecewise-linear interpolation with an arbitrary set \( x_k \), \( k = 1, \ldots, K \) of \( K \) nodes (i.e., CD4 count values at which the linear functions are joined):

\[
m_1 + \sum_{k=1}^{K} \left( \beta_{k-1} - u_1 + \left( \beta_k - \beta_{k-1} \right) \frac{CD4 - x_{k-1}}{x_k - x_{k-1}} \right) I(x_{k-1} < CD4 \leq x_k)
\]

where \( I(\cdot) \) is the indicator function and \( \beta_0 = u_1 \); parameters \( \beta_k \) referring to the logarithms of odds of changing the HPV status for CD4 = \( x_k \). This model tests whether different shapes of interrelations between CD4 counts and probability of HPV clearance are possible in HIV-1-positive patients at a very low (<200 cells/mm³), low (200–499 cells/mm³), and normal range of CD4 counts.

\[ M6 \] —includes the logarithm of HIV-1 VL (\( u_1 + \beta_1 \cdot CD4 + \beta_2 \cdot \log(VL) \)) to evaluate the effect of HIV-1 VL on probability of HPV clearance in HIV-1-positive patients controlling the level of CD4 count.
### Table 2. Incident and prevalent HPV infection, by subtype, in the REACH cohort.

| Variable | HIV-1-positive (n = 262) | HIV-1-negative (n = 134) |
|----------|--------------------------|--------------------------|
|          | Non-infected             | Prevalent infection       | Incident infection | Non-infected | Prevalent infection | Incident infection |
|          |                          |                          |                   |              |                   |                   |
| HPV16/16-like |                          |                          |                   |              |                   |                   |
| HPV16    | 177 (67.6%)              | 45 (17.2%)               | 40 (15.3%)        | 108 (80.6%)  | 7 (5.2%)           | 19 (14.2%)        |
| HPV31/33/35 | 166 (63.4%)              | 39 (14.9%)               | 57 (21.8%)        | 105 (78.4%)  | 12 (9.0%)          | 17 (12.7%)        |
| HPV52    | 197 (75.2%)              | 31 (11.8%)               | 34 (13%)          | 117 (87.3%)  | 4 (3.0%)           | 13 (9.7%)         |
| HPV58    | 182 (69.5%)              | 43 (16.4%)               | 37 (14.1%)        | 102 (76.1%)  | 12 (9.0%)          | 20 (14.9%)        |
| HPV67    | 240 (91.6%)              | 2 (0.8%)                 | 20 (7.6%)         | 131 (97.8%)  | 1 (0.7%)           | 2 (1.5%)          |
| HPV18/18-like |                          |                          |                   |              |                   |                   |
| HPV18    | 199 (76.0%)              | 20 (7.6%)                | 43 (16.4%)        | 112 (83.6%)  | 10 (7.5%)          | 12 (9.0%)         |
| HPV39    | 232 (88.5%)              | 11 (4.2%)                | 19 (7.3%)         | 128 (95.5%)  | 1 (0.7%)           | 5 (3.7%)          |
| HPV45    | 218 (83.2%)              | 13 (5.0%)                | 31 (11.8%)        | 119 (88.8%)  | 3 (2.2%)           | 12 (9.0%)         |
| HPV51    | 221 (84.4%)              | 7 (2.7%)                 | 34 (13.0%)        | 115 (85.8%)  | 4 (3.0%)           | 15 (11.2%)        |
| HPV59/68/70 | 170 (64.9%)              | 28 (10.7%)               | 64 (24.4%)        | 105 (78.4%)  | 7 (5.2%)           | 22 (16.4%)        |
| HPV26/69 | 221 (84.4%)              | 6 (2.3%)                 | 35 (13.4%)        | 124 (92.5%)  | 3 (2.2%)           | 7 (5.2%)          |
| HPV56/56-like |                          |                          |                   |              |                   |                   |
| HPV56    | 215 (82.1%)              | 20 (7.6%)                | 27 (10.3%)        | 123 (91.8%)  | 3 (2.2%)           | 8 (6.0%)          |
| HPV53/66 | 142 (54.6%)              | 40 (15.3%)               | 79 (30.2%)        | 103 (76.9%)  | 5 (3.7%)           | 26 (19.4%)        |
| HPV low-risk |                          |                          |                   |              |                   |                   |
| HPV6/11/42/44 | 178 (67.9%)              | 32 (12.2%)               | 52 (19.8%)        | 109 (81.3%)  | 11 (8.2%)          | 14 (10.4%)        |
| HPV54/40 | 191 (72.9%)              | 10 (3.8%)                | 61 (23.3%)        | 114 (85.1%)  | 4 (3.0%)           | 16 (11.9%)        |
| HPV13/32 | 222 (84.7%)              | 2 (0.8%)                 | 38 (14.5%)        | 127 (94.8%)  | 1 (0.7%)           | 6 (4.5%)          |
| HPV62/72 | 224 (85.5%)              | 5 (1.9%)                 | 33 (12.6%)        | 128 (95.5%)  | 1 (0.7%)           | 5 (3.7%)          |
| HPV52/57 | 252 (96.2%)              | 1 (0.4%)                 | 9 (3.4%)          | 134 (100%)   | 0                 | 0                 |
| HPV55    | 250 (95.4%)              | 0                        | 12 (4.6%)         | 131 (97.8%)  | 0                 | 3 (2.2%)          |

Notes: results are presented as number of cases (percent); *p < 0.05 for the difference between HIV-1-positive and HIV-1-negative; categorical variables were analyzed by chi-square.

doi:10.1371/journal.pone.0030736.t002

### Table 3. Hazard ratios for HPV infection clearance probability for HIV-1-infected adolescent females from the REACH cohort, univariable and multivariable Cox proportional hazard regression (results are presented with 95% CIs).

| Parameter | HPV16/16-like | HPV18/18-like | HPV56/56-like | HPV low risk |
|-----------|---------------|---------------|---------------|--------------|
|           | Univariable   | Multivariable | Univariable   | Multivariable | Univariable   | Multivariable | Univariable   | Multivariable | Univariable   | Multivariable |
| CD4/100 (per each 100 cells/mm³ increase) | 1.08(1.06,1.10) | 1.15(1.08,1.23) | 1.05(1.03,1.08) | 1.34(1.24,1.45) | ns            | ns            | 1.11(1.08,1.14) | 1.24(1.12,1.36) |
| CD4 level ≤200 cells/mm³ (vs. <200 cells/mm³) | 1.68(1.32,2.14) | n/a           | 1.80(1.40,2.31) | n/a           | ns            | ns            | 2.53(1.81,3.53) | n/a           |
| CD4 level >500 cells/mm³ (vs. <500 cells/mm³) | 1.65(1.42,1.91) | n/a           | 1.70(1.45,1.98) | n/a           | ns            | ns            | 2.11(1.74,2.57) | n/a           |
| HIV-1 VL | 0.82(0.76,0.88) | ns            | 0.79(0.73,0.86) | ns            | ns            | ns            | 0.74(0.67,0.81) | ns            |
| HAART    | ns            | 1.42(1.22,1.66) | ns            | ns            | ns            | ns            | ns            | ns            |
| HAART with PI | 1.57(1.33,1.84) | 1.77(1.50,2.08) | 1.75(1.47,2.08) | 1.79(1.50,2.13) | ns            | ns            | 1.68(1.36,2.08) | 1.82(1.47,2.27) |
| Any HPV infection at baseline | ns            | ns            | ns            | ns            | ns            | ns            | ns            | ns            |
| Chlamydia trachomatis | ns            | ns            | ns            | ns            | ns            | ns            | 1.69(1.33,2.14) | 1.60(1.26,2.02) |

Note: *p < 0.05; †p < 0.001; ns - not significant; n/a – not applicable.
doi:10.1371/journal.pone.0030736.t003
M7) are presented in Table S1. The probability of HPV clearance in HIV-1-infected patients increased with increasing CD4 level for all HPV groups: parameter \( \beta_1 \) (the log odds ratio, describing the effect of CD4 count on HPV clearance) was 1.15 (0.27) for HPV16/16-like, 0.72 (0.36) for HPV18/18-like, 0.55 (0.31) for HPV56/56-like, and 0.66 (0.42) for low-risk HPVs (see Table 5). The interrelations between probability of clearance of oncogenic HPVs and CD4 likely had a piecewise shape for CD4 count <300 cells/mm\(^3\) (see Table S1). The effect of HIV-1 VL was minor on HPV16/16-like clearance (p = 0.061) and significant for low-risk HPV (p < 0.05) (the M6 model, Table 4). A minor effect of HAART with PIs was observed on HPV16/16-like (p = 0.060) clearance (the M7 model, Table 4).

When two oncogenic groups of HPV infections—HPV16/16-like and HPV18/18-like—were analyzed for each HPV type separately, both groups showed heterogeneity in terms of how probability of type-specific HPV clearance was affected by CD4 counts, HIV VL, and HAART with PI (see Table 6); while lower clearance probability was registered for HPV16/16-like than for the 18/18-like group (p < 0.05). Interestingly, HPV16 and HPV18 alone had an equal chance to be cleared at all CD4 levels examined; i.e., 20.29 (3.76)% and 18.16 (4.04)% at CD4 level 200 cells/mm\(^3\), and 34.12 (3.49)% and 42.12 (6.24)% at CD4 level 600 cells/mm\(^3\), for HPV16 and HPV18, respectively. The effect of HIV-1 VL was significant for clearance of HPV58 (16-like group) and HPV59 (18-like group), and the effect of HAART (with PIs) was significant for HPV16 clearance. In average, HPV67 had a higher probability to be cleared than the other 16/16-like HPV types; e.g., 64.11 (15.72)% vs. 25.76 (1.48)% at CD4 level 400 cells/mm\(^3\) (p < 0.05). Likewise, HPV18 had the lowest probability to be cleared (18.16 (4.04)%), and HPV26 the highest (42.12 (8.39)%)) than other 18/18-like HPV types at CD4 level 200 cells/mm\(^3\) compared to the group at average (27.40 (2.38)%), p < 0.05.

**Discussion**

The longitudinal studies of HPV infection are important for determining the covariates and outcomes associated with HPV persistence, which leads to the development of cancer. Traditionally, the rate of HPV clearance are usually compared in HIV-1-positive patient subgroups based on baseline CD4 counts (such as

![Figure 2. The 3-month HPV type-specific probability of clearance depending on CD4 T-lymphocytes in HIV-1-positive adolescent girls from the REACH cohort.](doi:10.1371/journal.pone.0030736.g002)
The approaches utilizing the generalized estimating equation (GEE)—they take into account the mutual correlations in the time of incidence, clearance, and censoring events could be reconstructed (as it is required for Kaplan-Meier and Cox analyses). The shorter intervals accessible in our method allow for taking into account the dynamics of potential predictors, which could change quickly (such as CD4 count, HIV-1 VL, and HAART regimen). This model allows for calculating the clearance probability with subsequent confirmation in another 3 months—$P_{100}(x)$—by transferring the probabilities such as $P_{100}(x)=P_{10}(x)$, thus corresponding to the routine definition of HPV clearance when the absence of HPV type-specific infection is required for two subsequent visits. Opposite to the Cox model, in which HRs are estimated for time-dependent covariates, the developed approach allows us to estimate the transition probability and evaluate its standard errors. Since the developed model provides the hazard function for probability of HPV infection clearance, the respective survival function and characteristics of time-to-clearance distribution also can be evaluated: e.g., time to clearance (in months) could be estimated as $3/P_{10}(x)$, and a median of HPV clearance time as $3\log(2)/P_{10}(x) \approx 2.1/P_{10}(x)$. The approaches utilizing the generalized estimating equation (GEE)—they take into account the mutual correlations in

### Table 5. Probability of HPV clearance (in %, ±SE) at specific CD4 levels, by phylogenetic HPV group, in HIV-1-positive adolescent females, REACH cohort.

| CD4 cell (cells/mm³) | HPV16/16-like | HPV18/18-like | HPV56/56-like | Low-risk HPV |
|----------------------|---------------|---------------|---------------|--------------|
| 200                  | 21.60±1.81    | 27.40±2.38*   | 29.96±3.30*   | 26.60±2.79*  |
| 500                  | 28.03±1.47    | 37.77±2.08*   | 34.66±2.51*   | 36.24±2.50*  |
| 750                  | 34.19±2.24    | 47.42±3.57*   | 38.83±3.50    | 45.26±4.11*  |
| 1000                 | 40.93±3.69    | 57.27±5.44*   | 43.17±5.45    | 54.60±6.28*  |
| 1500                 | 55.22±6.84    | 74.74±7.46*   | 52.09±9.95    | 71.80±9.06*  |

Note: *The difference with HPV16/16-like type is significant (p<0.05).

doi:10.1371/journal.pone.0030736.t005

| CD4 cell (cells/mm³) | HPV16/16-like | HPV18/18-like | HPV56/56-like | Low-risk HPV |
|----------------------|---------------|---------------|---------------|--------------|
| 200                  | 21.60±1.81    | 27.40±2.38*   | 29.96±3.30*   | 26.60±2.79*  |
| 500                  | 28.03±1.47    | 37.77±2.08*   | 34.66±2.51*   | 36.24±2.50*  |
| 750                  | 34.19±2.24    | 47.42±3.57*   | 38.83±3.50    | 45.26±4.11*  |
| 1000                 | 40.93±3.69    | 57.27±5.44*   | 43.17±5.45    | 54.60±6.28*  |
| 1500                 | 55.22±6.84    | 74.74±7.46*   | 52.09±9.95    | 71.80±9.06*  |

Note: *The difference with HPV16/16-like type is significant (p<0.05).

doi:10.1371/journal.pone.0030736.t005

### Table 6. CD4 T-lymphocyte counts (basic model M1), HIV VL (M6 model), and HAART (M7 model) effects on HPV clearance probability, HPV type-specific, in HIV-1-positive adolescent females, REACH cohort.

| HPV type               | M1 (basic model): CD4 effect | M6 model: HIV VL effect, | M7 model: HAART(PI) effect |
|------------------------|-------------------------------|----------------------------|----------------------------|
| HPV16/16-like group    |                               |                            |                            |
| HPV16                  | $-1.72(0.33)**$               | $1.78(0.56)**$             | $0.99(0.38)**$             |
| HPV31                  | $-1.55(0.32)**$               | $0.97(0.55)*$              | $0.14(0.17)$               |
| HPV52                  | $-1.42(0.31)**$               | $1.28(0.56)**$             | $0.25(0.2)$                |
| HPV58                  | $-1.54(0.28)**$               | $0.82(0.48)*$              | $0.53(0.22)**$             |
| HPV67                  | ns                            | ns                         | $-8.46(8.3)$               |
| HPV16/16-like          |                               |                            |                            |
| HPV16                  | $-1.52(0.15)**$               | $1.15(0.27)**$             | $0.17(0.09)$               |
| HPV18/18-like group    |                               |                            |                            |
| HPV18                  | $-2.10(0.42)**$               | $2.97(0.89)**$             | $0.37(0.28)$, $p=0.188$    |
| HPV59                  | $-0.78(0.58)$                 | $1.97(1.24)$               | ns                         |
| HPV45                  | $-1.66(0.5)**$                | $3.03(1.13)**$             | $0.03(0.24)$               |
| HPV51                  | $-1.41(0.53)**$               | $1.61(1.05)$               | $0.62(0.39)**$             |
| HPV59                  | $-1.12(0.31)**$               | $0.86(0.56)*$              | $-0.43(0.2)**$             |
| HPV26                  | $-0.49(0.51)$                 | $0.87(1.10)$               | $-0.08(0.4)$               |
| HPV18/18-like          | $-1.29(0.18)**$               | $1.58(0.36)**$             | $-0.14(0.12)$              |

Note: * $0.05 \leq p < 0.1$; ** $p < 0.05$. $\beta_{u1}$, $\beta_{p1}$, $u_{11}$, and $\beta_{11}$, are related to the parameters in equation (2).

*– the units of $\beta_{p1}$ and $\beta_{11}$ are 1000/[C], where [C] are the units of CD4 cell counts, i.e., cells/mm³; b – non-significant.

SEs were obtained by re-estimating the model in which probability at specific value of CD4 cell count was chosen as a model parameter instead of $\beta_{11}$.

doi:10.1371/journal.pone.0030736.t006
clearance of different HPV types and modeling mixed effects, allowing individuals to have their own characteristics (i.e., distributed in a population) — could be used to further enrich the developed base model; Xue et al. [26] recently reviewed the series of approaches that can be used for similar generalizations.

In both approaches, a transitional probability-based model and Cox regression model, CD4 count was a significant predictor of clearance of all phylogenetic HPV groups in HIV-1-infected adolescent females; also, certain effects of HAART (with PI) on clearance of HPV16/16-like and HPV18/18-like infections were observed. However, while in the Cox model, being HIV-1-infected had a minor effect only on HPV56/56-like clearance, in the transitional probability model, this factor was a significant predictor of clearance of HPV16/16-like, HPV56/56-like, and low-risk HPVs.

In immunodeficient patients, the mechanisms by which immune deficiency increases the risk of persistence of HPV infection are still poorly understood: some alterations in dendritic antigen-presenting cells, Langerhans cells, and macrophages function, as well as a deficient cytotoxic lymphocyte response to E6 and E7 proteins, might be the contributing factors [27,28]. The results obtained from our study about the role of CD4 in HPV clearance corroborate previous reports from the REACH cohort, as well as several other studies on adult HIV-infected females [1,2,29,30,31,32,33,34]. However, there is no agreement about the role CD4 play in clearance of individual types of HPV; e.g., in several studies on both HIV-1-negative and HIV-1-positive females, it has been shown that HPV16 infection has a lower probability of clearance than other HPV types, possibly due to its greater ability to escape immunologic surveillance [35,36,37], while other studies did not demonstrate such a difference [38].

In our study, a lower clearance probability was registered for the HPV16/16-like than for the 18/18-like group, while HPV16 had an equal-with-HPV18 chance to be cleared at both pathologic and normal CD4 counts. The observed heterogeneity of phylogenetic groups of HPV infection in terms of a probability of HPV clearance may depend not only on CD4 counts and other predictors measured at current time (such as HIV-1 VL and HAART with PI), but also from the history of HPV type-specific infection (e.g., from the time since HPV acquisition, which is an unobserved variable), depending on a prevalent or incident type-specific HPV infection. Further analysis could be performed using non-Markov approaches to model unobserved time since HPV acquisition.

HIV infection, independent of CD4 count, has also been suggested to be a predictor of persistence of HPV infection in HIV-1-positive women. This may imply an alternate mechanism besides CD4, e.g., via alteration of the cytokine response to HPV infection in the cervical mucus [2,39,40,41,42]. In our study, being HIV-1-positive affected the probability of clearance of HPV16/16-like, 18/18-like, and low-risk HPV's. In the REACH cohort-based study by Moscicki et al. [2], when only subjects with normal CD4 counts (i.e., ≥500 cells/mm³) were considered, the multivariable regression showed high significance of HIV status as an independent predictor of HPV clearance event (HR = 1.60, p = 0.012).

Currently, prognostic importance of high HIV-1 VL for HPV clearance is not clear, but it likely increases the risk of persistence of HPV infection at low CD4 cell counts [32,43]. In our study, HIV-1 VL could affect the clearance of low-risk HPVs and certain oncogenic HPV's (e.g., HPV58 and HPV59). The apparent impact of HAART on HPV incidence, clearance, and persistence also is not clear [11,23,32,44,45]. In our study, when HAART was analyzed taking into account its PI component, a significant effect was observed for HPV16, and minor effects were observed for HPV16/16-like, HPV18/18-like, and HPV59. In vitro studies have shown that specific PI's inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells [46]. Previous crossover analyses in REACH suggested no significant effect of HAART on HPV clearance [11]; however, the effect of PI was not examined, as it is incorporated in this new method. These results require further investigation with longer follow up and more detailed analysis of HAART/PI history and dose/exposure.

The observation on C. trachomatis increasing probability of clearance of low-risk HPV falls in with the results from animal studies about potential role of interferon-γ as local “protector” against other (i.e., non-Chlamydia) infections [47,48]. Oncogenic HPV types could be strong enough to avoid this mechanism; recently, it has been speculated that C. trachomatis could have effect on oncogenic HPV types [49].

The results of this study have several limitations. While the prevalence and incidence of HPV infections among HIV-1-positive adolescents in the REACH study is high [11], some of the associations may have been limited by the relatively smaller sample size of HIV-1-negative individuals along with the lower HPV infection rate. Due to the populations served at the REACH recruitment sites, young African-American women were a significant proportion of the population; therefore, the results may not be fully generalized to other populations. Also, the interrelations described in this study were obtained on a cohort of young adolescent girls with relatively short histories of HIV-1 infections, who are generally healthy and whose immune response to the infection may differ from older women; for example, it has been shown in several studies that older age was associated with higher risk of HPV persistence in both HIV-infected and HIV-uninfected women [24,50]. Regarding the approach, the simple version of the model was intentionally chosen as a base model, resulting in some limitations; e.g., there was no distinction between the effects of incident infection and re-infection, no correlations between clearance of distinct HPV types in one individual were modeled, and the time after the incidence was not explicitly represented. Due to the two-step design of the study, some variables which were statistically insignificant were not included into the second step of the analysis thus potentially compromising the robustness of the model. Nevertheless, the limitations can be overcome by the extensions of the proposed approach using approaches specifically developed for analyses of HPV clearance [26] and those that were successfully used in other related research areas, e.g., g-formula [16] or a (binomial) stochastic process model [51,52,53].

In summary, our new model estimates a probability for HPV clearance of type-specific HPV groups at 3-month period by coordinating uneven time scales of measurements on biannual HPV status and other quarterly HIV-1-related clinical data and risk factors.

Supporting Information

Table S1: HPV type-specific characteristics obtained from the M1 – M7 models tested in the REACH cohort of HIV-1-positive and HIV-1-negative adolescent girls enrolled in 1996-2000.

Acknowledgments

The authors thank the investigators and staff [listed in J. Adolesc Health 2001;29 (suppl): 5 to 6] of the Adolescent Medicine HIV/AIDS Research Network (1994–2001) and the youth who participated in the REACH project for their valuable contributions.

PLoS ONE | www.plosone.org 9 January 2012 | Volume 7 | Issue 1 | e30736
References

1. Abdelh I, Manouz A, Vlahov D, Trimble CL, Timpson LA, et al. (2000) Cervical neoplasia and repeated positivity of human papillomavirus infection in human immunodeficiency virus-seropositive and -seronegative women. Am J Epidemiol 151: 1149–1157.

2. Moscicki AB, Ellenberg JH, Farhat S, Xu J (2004) Persistence of human papillomavirus infection in HIV-infected and uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 190: 37–45.

3. Schiffman MH, Castle P (2005) Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 95: E2.

4. Woodman CB, Collins SJ, Young LS (2007) The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7: 11–22.

5. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, et al. (1995) Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 87: 1365–1371.

6. Kulmala SM, Shabalova IP, Petroviches N, Syrjanen KJ, Gyllensten UB, et al. (2007) Type-specific persistence of human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 335: 572.

7. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rosendaal L, Voorhuis EJ, et al. (2001) Cytological regression and clearance of high-risk human papillomavirus infection in women with an abnormal cervical smear. Lancet 358: 1782–1783.

8. Kotloff KL, Wasserman SS, Russ K, Shapiro S, Daniel R, et al. (1998) Detection of genital human papilloma virus and associated cytological abnormalities among college women. Sex Transm Dis 25: 241–250.

9. Rogers AS, Futterman DK, Moscicki AB, Wilson CM, Ellenberg J, et al. (1998) The REACH Project of the Adolescent Medicine HIV/AIDS Research Network: design, methods, and selected characteristics of participants. J Adolesc Health 22: 300–311.

10. Shrestha S, Sudegna SL, Smith JS, Bachman LH, Wilson CM, et al. (2005) The impact of highly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIV-positive adolescents. BMC Infect Dis 10: 295.

11. Vermund SH, Kelley KF, Klein RS, Feingold AR, Schreiber K, et al. (1991) High risk of human papillomavirus infection and cervical squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection. Am J Obstet Gynecol 165: 1380–1387.

12. Rowhani-Rahbar A, Hawes SE, Sow PS, Toure P, Feng Q, et al. (2007) Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. J Infect Dis 190: 1413–1421.

13. Van Ranst M, Kaplan JB, Burk RD (1992) Phylogenetic classification of human papillomaviruses: correlation with clinical manifestations. J Gen Virol 73(Pt 10): 2655–2660.

14. Murphy DA, Wilson CM, Durako SJ, Muerz LR, Belzer M (2001) Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care 13: 27–40.

15. Roman GE (1987) Logistic regression for dependent binary observations. Biometrics 43: 951–973.

16. Taubenblatt ML, Robbins JM, Mintzeman MA, Hernan MA (2009) Interviewing on risk factors for coronary heart disease: an application of the parametric g-formula. Int J Epidemiol 38: 1599–1611.

17. Kong X, Archer KJ, Moulton LH, Gray RH, Wang MC (2010) Parametric frailty models for clustered data with arbitrary censoring: application to effect of male circumcision on HPV clearance. BMC Medical Research Methodology 10: 40.

18. Lehitten M, Linikkaala T, Wallin KL, Paavonen J, Thoresen S, et al. (2001) Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction. J Clin Virol 22: 117–124.

19. Polack PF, Dummer JS, Pai CH, Bollinger RR, et al. (2002) Efficacy of an HIV-1 type 1 vaccine in HIV-1-seronegative and -seropositive individuals: a phase 3, double-blind, randomised controlled trial. Lancet 359(9308): 184: 682–690.

20. Williams DA (1975) The analysis of binary responses from toxicological experiments involving reproduction and teratogenicity. Biometrics 31: 940–932.

21. Xu X, Gange SJ, Zhong Y, Burk RD, Minkoff H, et al. (2004) Effect of the use of the anal canal for the morphologic evaluation of human papillomavirus natural history data. Cancer Epidemiol Biomarkers Prev 19: 159–169.

22. Nakagawa M, Sites DP, Farhat S, Sider JR, Moss B, et al. (1997) Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. The Journal of infectious diseases 175: 927–931.

23. Sobhani I, Walker F, Roudot-Thoraval F, Abramowitz L, Jhanet H, et al. (2004) Anal carcinoma: incidence and effect of cumulative infections. AIDS 18: 1561–1569.

24. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, et al. (1997) Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 337: 1345–1349.

25. Moscicki AB, Ellenberg JH, Crowley-Nowick P, Darragh TM, Xu J, et al. (2004) Risk of high-grade squamous intraepithelial lesion in HIV-infected adolescents. J Infect Dis 190: 1413–1421.

26. Soltani H, Walker F, Roudot-Thoraval F, Abramowitz L, Jhanet H, et al. (2004) Anal carcinoma: incidence and effect of cumulative infections. AIDS 18: 1561–1569.

27. Sun XW, Ellerbrock TV, Lungo O, Chiasson MA, Bush TJ, et al. (1995) Human papillomavirus infection in human immunodeficiency virus-seropositive women. Obstet Gynecol 85: 680–686.

28. Ferrerena JS, van Ameijde MT, Koninghio RA, van den Hoek AA (1995) HIV, sexually transmitted diseases and gynaecologic disorders in women: increased risk for genital herpes and warts among HIV-infected prostitutes in Amsterdam. Aids 9: 1071–1074.

29. Mollan M, Van den Brule A, Plummer M, Weiderpass E, Pesso H, et al. (2003) Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 158: 486–494.

30. Strickler HD, Palefsky JM, Shah KV, Anastos K, Klein RS, et al. (2003) Human papillomavirus type 16 and 18 related cervical disease in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 95: 1062–1071.

31. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, et al. (2005) The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337: 76–84.

32. Franco EL, Villa LL, Sobrino JP, Prado JM, Rousseau MC, et al. (1999)VP1-based prospective follow up study. BMJ 325: 572.

33. Ruymann FJ, et al. (2001) Cytological regression and clearance of high-risk human papillomavirus infection in HIV-infected individuals Human Papillomavirus: Springer-Verlag Berlin and Heidelberg GmbH & Co. K. pp 163–177.
46. Hampson L, Kitchener HC, Hampson IN (2006) Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antiviral Therapy 11: 813–825.
47. Johansson M, Schon K, Ward M, Lycke N (1997) Studies in knockout mice reveal that anti-chlamydial protection requires TH1 cells producing IFN-gamma: is this true for humans? Scandinavian Journal of Immunology 46: 546–552.
48. Su H, Caldwell HD (1995) CD4+ T cells play a significant role in adoptive immunity to Chlamydia trachomatis infection of the mouse genital tract. Infection and Immunity 63: 3302–3308.
49. Koskela P, Anttila T, Bjorge T, Brunsvig A, Dillner J, et al. (2000) Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. International journal of cancer Journal international du cancer 85: 35–39.
50. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD (1998) Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338: 423–428.
51. Yashin AI, Arbeev KG, Akushevich I, Kulminski A, Akushevich L, et al. (2007) Stochastic model for analysis of longitudinal data on aging and mortality. Mathematical Biosciences 208: 538–551.
52. Yashin AI, Manton KG (1997) Effects of unobserved and partially covariate processes on system failure: A review of Models and estimation strategies. Statistical Science 12: 20–34.
53. Akushevich I, Kulminski A, Manton K (2005) Life Tables with Covariates: Dynamic Model for Nonlinear Analysis of Longitudinal Data. Mathematical Population Studies 12: 51–80.